

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Off. : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi -110058
CIN : U85191DL2011PLC216530

Dated: 31.10.2017

<p>The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 Trading Symbol: AGLSL</p>	<p>The Secretary BSE Ltd PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400001 Scrip Code:540616</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------

Sub: Outcome of the Board Meeting held on 31st October, 2017

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 we wish to inform you that Board of Directors of the Company in their meeting held on 31.10.2017 have inter alia, considered and approved the unaudited financial results for the quarter and half year ended 30th September, 2017 as recommended by Audit Committee.


Further Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results, along with the Limited Review report thereon is enclosed.

The Board Meeting commenced at 4:00 p.m. and concluded at 4:40 p.m.

Please take the above information on your records.

Thanking you
Yours Faithfully

For Artemis Global Life Sciences Ltd.



Anuj Sood
Company Secretary (A35276)
D-6/10, 3rd Floor Rana Pratap Bagh,
Delhi-110007

Corporate off : SF-202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon - 122002

Website : www.aglsl.in ♦ E-mail: investor@aglsl.in ♦ Tel. 0124 - 4262305/07 ♦ Fax. 0124 - 4262306

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Ph: 47021279

Limited Review Report

To,
The Board of Directors,
Artemis Global Life Sciences Limited

We have reviewed the accompanying statement of unaudited financial results of **Artemis Global Life Sciences Limited** for the quarter and half year ended on 30th September, 2017 and unaudited Balance Sheet as on 30th September, 2017 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 31.10.2017

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N



(Anand Dua)
Partner
M.No. 083503

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Off. 414/1 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi -110058
CIN : U85191DL2011PLC216530

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017

PART I		RS. LACS					
SL.NO.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
		(UNAUDITED)	(UNAUDITED)	Refer Note 3	(UNAUDITED)	Refer Note 3	(AUDITED)
1	Revenue from Operations*	10.20	10.20	10.20	20.40	20.40	40.80
2	Other Income	-	19.23	-	19.23	-	-
3	Total Income from Operations (I+II)	10.20	29.43	10.20	39.63	20.40	40.80
4	Expenses						
	(a) Employee benefits expense	3.75	3.73	-	7.48	-	-
	(b) Finance Cost	-	-	-	-	-	-
	(c) Depreciation and Amortisation Expense	3.76	3.41	3.68	7.17	7.36	14.71
	(d) Other Expenses	8.94	9.99	0.31	18.94	0.90	4.97
	Total Expenses (IV)	16.46	17.13	3.99	33.59	8.26	19.68
5	Profit / (Loss) from Operations before Exceptional Items and Tax (I-IV)	(6.26)	12.30	6.21	6.04	12.14	21.12
6	Exceptional Items	11.38	-	-	11.38	-	-
7	Profit/(Loss) from Ordinary Activities before Tax (5-6)	(17.64)	12.30	6.21	(5.34)	12.14	21.12
8	Tax Expense	(1.80)	3.33	1.58	1.52	3.16	6.31
9	Net Profit/(Loss) from Ordinary Activities after Tax (7-8)	(15.84)	8.97	4.63	(6.87)	8.98	14.81
10	Extraordinary Items (Net of Tax expenses)	-	-	-	-	-	-
11	Net Profit/(Loss) for the Period (9-10)	(15.84)	8.97	4.63	(6.87)	8.98	14.81
12	Other comprehensive income (net of tax)						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive income	(15.84)	8.97	4.63	(6.87)	8.98	14.81
14	Paid-up Equity Share Capital (Equity Shares of Rs.2/-each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
15	Reserves excluding Revaluation Reserves	**	**	**	**	**	14,568.78
16	EARNINGS PER SHARE (EPS)						
	Basic EPS before & after Extraordinary Items (Not Annualized) -Rs	(0.02)	0.01	0.01	(0.01)	0.01	0.02
	Diluted EPS before & after Extraordinary Items (Not Annualized) -Rs	(0.02)	0.01	0.01	(0.01)	0.01	0.02

* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

** Not required to be shown

De

Corporate off : SF-202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon - 122002

Website : www.aglsl.in ♦ E-mail: investor@aglsl.in ♦ Tel. 0124 - 4262305/07 ♦ Fax 0124 - 4262306

**ARTEMIS GLOBAL LIFE SCIENCES LIMITED (FORMERLY KNOWN AS PTL PROJECTS LIMITED)
STATEMENT OF ASSETS AND LIABILITIES**

	INR LACS	
	Sep. 30, 2017 (UNAUDITED)	March 31, 2017 (AUDITED)
Assets		
Non-current assets		
Property, plant and equipment	184.94	192.11
Financial assets		
i. Investments	15,990.62	15,990.62
Other non-current assets	-	-
Total non-current assets	16,175.55	16,182.72
Current assets		
Financial assets		
i. Trade receivables	11.55	-
ii. Cash and cash equivalents	20.10	51.73
Current tax assets (Net)	2.14	0.86
Other current assets	4.61	-
Total current assets	38.40	52.59
Total Assets	16,213.95	16,235.31
Equity and liabilities		
Equity		
Equity share capital	1,323.77	1,323.77
Other equity		
Reserves & Surplus	14,552.94	14,559.81
Total equity	15,876.71	15,883.58
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Other financial liabilities		
Deferred tax liabilities	6.40	23.82
Total non-current liabilities	6.40	23.82
Current liabilities		
Financial liabilities		
i. Trade payables	1.11	-
Provisions	6.45	2.48
Other current liabilities	323.29	325.43
Total current liabilities	330.85	327.91
Total liabilities	337.25	351.73
Total equity and liabilities	16,213.95	16,235.31

or

NOTES:

- 1 The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
- 2 The scheme of arrangement under sections 391 to 394 of the Companies Act, 1956 read with section 230 to 232 Companies Act, 2013 (the Scheme) between Artemis Global Life Sciences Limited (the Company) and PTL Enterprises Limited (the Demerged Company) and their respective shareholders and the creditors of the two companies for demerger of Medicare and Healthcare Services Business undertaking as a going concern into the Company with the Appointed Date at the opening of business hours on 01st April 2016, has been sanctioned by the Hon'ble High Court of Judicature at Kerala vide its Order dated 16th December, 2016, and the Hon'ble National Company Law Tribunal, New Delhi vide its Order dated 1st March, 2017. Certified copies of the order of the Hon'ble High Court of Judicature at Kerala and Hon'ble National Company Law Tribunal, New Delhi have been filed with the Registrar of Companies at Kerala and Delhi respectively and the scheme has become effective from 8th March 2017. Hence, 5,00,000 Equity Shares of Rs 2 (Indian Rupees Two Only) each fully paid up of the Company were Cancelled, and 6,61,88,500 equity shares of Rs. 2 (Indian Rupees Two Only) each were allotted to the shareholder of the Demerged Company on March 30, 2017 in the ratio of 1 (One) equity share in Company for every 1 (One) equity shares of Rs. 2/- (Indian Rupees Two Only) each held in the Demerged Company. Accordingly the paidup capital of the Company is Rs. 1323.77 Lacs.
- 3 The results incorporate the impact of the above mentioned demerger from the appointed date April 1, 2016. The results for the quarter ended June 30, 2016, quarter ended September 30, 2016 and half year ended September 30, 2016 have also been restated accordingly to incorporate the impact of demerger.
- 4 The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and other recognised accounting practices and the policies to the extent applicable. Being April 1, 2017 company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- 5 The Ind AS compliant corresponding figures for the quarter and half year ended Sep 30, 2016, have not been subjected to limited review or audit. However the Company management has exercised necessary due diligence to ensure that such financials results provide a true and fair view of its affairs.
- 6 Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to Total Comprehensive Income in accordance

RS. LACS

S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDING	
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016
		(Refer Note 2)	(Refer Note 2)	(Refer Note 2)	(Refer Note 2)	(Refer Note 2)
	Profit for the period as per I GAAP	(15.84)	8.97	4.63	(6.87)	8.98
	Profit for the period under Ind AS	(15.84)	8.97	4.63	(6.87)	8.98
	Other Comprehensive income as per Ind AS	-	-	-	-	-
	Total Comprehensive income as per Ind AS	(15.84)	8.97	4.63	(6.87)	8.98

- 7 Reconciliation of equity as per Previous Indian GAAP (I GAAP) and as per Ind AS is given below

RS. LACS

S.No.	PARTICULARS	As At	As At
		31.03.2017	01.04.2016
		(Refer Note 2)	(Refer Note 2)
	Equity as per I GAAP	15,883.58	15,868.77
	Equity as per Ind AS	15,883.58	15,868.77

- 8 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 31, 2017. The stand-alone results of the Company have undergone limited review by the Statutory Auditors.

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar S Kanwar

ONKAR S KANWAR
CHAIRMAN

PLACE: GURUGRAM
DATE: OCTOBER 31, 2017